361P - Surgical outcomes of primary retroperitoneal sarcoma: an institutional experience

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Soft Tissue Sarcomas
Surgical Oncology
Radiation Oncology
Presenter Faith Leong
Citation Annals of Oncology (2015) 26 (suppl_9): 108-110. 10.1093/annonc/mdv530
Authors F.Q.H. Leong1, A. Rauff2, R. Parameswaran2
  • 1Division Of Endocrine And General Surgery, University Surgical Cluster, National University Hospital, 119074 - Singapore/SG
  • 2Division Of Endocrine And General Surgery, University Surgical Cluster, National University Hospital, Singapore/SG



Liposarcoma is the single most common soft tissue sarcoma in the retroperitoneum. We reviewed our experience with retroperitoneal liposarcoma to identify factors predictive of outcomes.


All patients with retroperitoneal liposarcoma (LPS) treated at a tertiary centre between 1998 and 2014 were reviewed. Multivariable Cox regression analyses were performed to identify factors predictive of relapse free survival (RFS) and overall survival (OS).


We identified 22 patients with primary retroperitoneal LPS. Median tumour size was 19.25 (± 9.62) cm; 27% were multifocal. Tumour grades were well differentiated in 55% of patients, pleomorphic in 22% of patients and high in 23%. Resections were complete (R0/R1) in 45% of patients and incomplete (R2) in 41% (unknown 14%). Resection of contiguous organs was required in 20 (91%) to achieve gross surgical margins. Median follow-up was 68 months. 15 patients (68%) experienced local recurrence or progression, with 45% occurring in the retroperitoneum. Cohort mortality was 32%. Mean RFS and OS were (41.83 ± 38.11) months and (67.50 ± 67.01) months, respectively, and were worse with R2 resection. On multivariate analysis only histotype was predictive of RFS.


In this cohort of primary retroperitoneal sarcoma, extent of surgical resection and histological grade impacted patient outcomes.

Clinical trial identification

Not applicable


All authors have declared no conflicts of interest.